Novel therapy for the treatment of optic neuropathies by inhibition of semaphorin3A
A Spanish research centre, has jointly developed with a Israeli university, a family of compounds able to inhibit Semaphorin3A fostering nerve regeneration after injury. These compounds can be useful for treatment of ischemic events such as stroke, glaucoma and other optical nerve and retina insults. Biotech or pharmaceutical companies are sought for license agreement and/or research collaboration to perform preclinical assays.
After a neuronal damage is produced, Semaphorin3A (Sema3A) protein is highly expressed as a response in adult mammalian central nervous system (CNS), preventing axon regeneration and promoting progressive neuronal apoptosis, even once the ischemic event is restored, leading to permanent damage.Compounds presented are able to modulate neurodegeneration by inhibiting Sema3A pathway, thus stimulating injured axons regeneration and brain repair.Their therapeutic potential has been proved in pre-clinical (in vitro and in vivo) assays involving injure of the optic nerve. The Sema3A inhibitors were able to prevent loss of retinal ganglion cells (RGC) in a range of harsh optic degenerative insults using in vivo models, such as optical nerve transection in adult rats. Results showed between 30-40% of RGC survival after treatment with the compounds. The research centres, with broad experience in medicinal chemistry and in ophtalmic research, are searching for a biotech or pharmaceutical company interested in the preclinical and clinical development of a treatment for optic neuropathies, under a license agreement. The centres could collaborate with the company in that project through a research collaboration.
Type and Role of Partner Sought:
Biotech or pharmaceutical companies interesed in the development of treatments for optic neuropathies.
- Licensing agreement: the partner would license the technology to perform clinical assays, obtain all regulatory certifications and commercialize the drug.
- Research cooperation agreement: the partner and the institution could undertake a joint effort to perform preclinical assays.